4D Molecular Therapeutics Inc


Market Cap$1.12B

Compare 4D Molecular Therapeutics

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
4D Molecular Therapeutics Inc4D Molecular Therapeutics Inc-11.70%-29%--
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Target Price by Analysts

141.4% upside4D Molecular Therapeutics Target Price DetailsTarget Price

Share Statistics

Market cap$1.12 Billion
Enterprise Value$814.78 Million
Dividend Yield$0.0 (0.0%)
Earnings per Share$-2.63
Outstanding Shares42,753,607
Avg 30 Day Volume2,294,973


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-11.67
Price to Sales-
Price to Book Ratio4.14
Enterprise Value to Revenue37.05
Enterprise Value to EBIT-7.76
Enterprise Value to Net Income-9
Total Debt to Enterprise0.02
Debt to Equity0.05

Revenue Sources

No data

ESG Score

No data

About 4D Molecular Therapeutics Inc

83 employees

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power o...